Entero Healthcare Solutions Limited (NSE:ENTERO) filed the transcript of its Q1 FY27 earnings conference call, held on 10 August 2026, under Regulation 30 of SEBI LODR. The call, hosted by Monarch Networth Capital, disclosed consolidated revenue of Rs 1,940 crore, up 38.2% year-on-year, and an EBITDA margin of 5% for the quarter ended June 30, 2026.
Key Highlights
- Consolidated revenue for Q1 FY27 grew 38.2% year-on-year to Rs 1,940 crore; on a like-for-like basis, growth was 40% year-on-year.
- EBITDA margin reached 5% for the quarter, with EBITDA growing 94% year-on-year, ahead of management's full-year FY27 guidance met in Q1 itself.
- Profit after tax stood at Rs 52 crore, up 72% year-on-year, with PAT attributable to owners at Rs 38 crore, up 37% year-on-year.
- Net working capital days improved to 61 days from 66 days a year ago; ROCE nearly doubled year-on-year from 11.5% to 21.1%.
About the Company
Entero Healthcare Solutions Limited (NSE:ENTERO), headquartered in Faridabad, Haryana, is a pharmaceutical and healthcare product distributor operating across 19 states in India. The company distributes over 83,400 SKUs from more than 3,000 manufacturers to over 72,000 retail and 2,300 hospital customers, supported by 138 warehouses across 475 districts. It also operates a MedTech segment where it plays a full commercial role.
Announcement in Detail
The transcript, filed under reference 34/SE/LC/2026-27 on 17 August 2026, covers the earnings call held on 10 August 2026 at 12:00 noon IST. Managing Director and CEO Prabhat Agrawal and Group CFO Dr. Balakrishnan Kaushik represented management. Gross margin expanded 147 basis points year-on-year to 11.4%, driven by scale-led procurement economies, a growing MedTech revenue share, and deliberate exit from low-margin accounts. Inorganic revenue growth was 20.4%, entirely from calendarisation of prior-year acquisitions, with no new acquisitions in Q1 FY27.
Management confirmed its full-year FY27 guidance of approximately 23% consolidated revenue growth (excluding new acquisitions), a 5% EBITDA margin, and 50% EBITDA-to-operating-cash-flow conversion. MedTech revenue is tracked to cross Rs 1,000 crore organically in FY27. Non-controlling interest stood at Rs 14 crore, approximately 27% of profit before minority interest, attributed to majority but not full buyouts in certain acquisitions.
Impact on Investors
Investors will note that the company achieved its stated full-year FY27 EBITDA margin guidance of 5% in Q1 itself, as disclosed during the call. The filing shows return on capital employed rose from 11.5% to 21.1% year-on-year, and ROE moved from 9% to 20.4%, indicating improved capital efficiency alongside revenue growth. Shareholders will observe that organic revenue growth of 17.8% on a reported basis comfortably exceeded underlying pharmaceutical market growth of 13.8%, as stated by management.
The disclosed terms indicate that non-controlling interest of Rs 14 crore reflects contractually structured majority buyouts in select subsidiaries, with pre-agreed call options for residual stake acquisition. Investors will note that minority profit shares are reinvested in the business rather than distributed, per management's disclosure on the call.
Sector / Market Context
India's pharmaceutical distribution sector remains highly fragmented, with organised players continuing to consolidate market share. Management cited underlying Indian pharmaceutical market growth of 13.8% for the quarter, contextualising Entero's organic outperformance. The broader healthcare logistics space has seen increasing adoption of technology-enabled supply chain models as per industry observations from bodies such as FICCI's health committee.